z-logo
open-access-imgOpen Access
Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results
Author(s) -
M.R. Weir,
P.A. McCullough,
J.B. Buse,
Jonathan H. Anderson
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/gj5n-9239
Subject(s) - canagliflozin , medicine , diabetes mellitus , type 2 diabetes , kidney disease , transporter , disease , endocrinology , empagliflozin , kidney , chemistry , biochemistry , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom